Successful development of therapeutics to target mucosally derived mediators would likely be of particular benefit to patients with noneosinophilic, noninflammed types of asthma where current treatments, aimed at modulating inflammation and IgE, are ineffective at modulating AHR and airway remodeling. Here, AHR is linked to asthma.